Implantable system for treprostinil: a real-world patient experience study

Area of Science:

• Cardiology
• Pulmonology
• Medical Devices

Background:

• Parenteral prostanoids are crucial for managing pulmonary arterial hypertension (PAH).
• External infusion pumps for treprostinil present significant patient burdens.
• An implantable system offers a less burdensome alternative for PAH treatment.

Purpose of the Study:

• To evaluate patient-reported outcomes with the Implantable System for Remodulin©.
• To assess changes in quality of life, daily activities, and social interactions.
• To understand patient perceptions of benefits and risks of the implantable system compared to external pumps.

Main Methods:

• A real-world study involving 20 pulmonary arterial hypertension patients.
• Patients transitioned from external pumps to the implantable system.
• Online surveys with quantitative and qualitative questions administered over six days.

Main Results:

• All patients reported improved quality of life, public confidence, and long-distance travel ability.
• Over 90% experienced enhanced independence and improved ability to perform daily activities.
• Qualitative feedback highlighted time savings, better relationships, and increased freedom.

Conclusions:

• The implantable system significantly improves patient-reported outcomes in PAH.
• This novel delivery system enhances quality of life, independence, and social well-being.
• The implantable system is a valuable advancement for managing pulmonary arterial hypertension.